• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Self-Insured Companies Missing Out on Massive Savings if Not Using Biosimilars, Report Says

Article

The analysis looked at 13 of America’s largest employers, including energy, hospitality, retail, transportation, and finance companies.

Self-insured companies could have saved $407 million to $1.4 billion in 2018 had they switched completely from reference biologics infliximab and filgrastim to biosimilars, according to a report from the ERISA Industry Committee.

The study also estimated potential savings for Medicare programs at $279 million in 2018.

“For the biosimilars market to promote price competition and successfully generate savings, it is important that plan sponsors reconsider their options based on the full savings potential offered by each product. Increased transparency and greater access to information are an important first step,” study authors said.

To read the full story, visit The Center for Biosimilars.

Related Videos
dr kimberly maxfield
Dr. Jorge Garcia
dr kimberly maxfield
Bincy Abraham, MD
Screenshot of Christine Pfaff, RPh, during a Zoom video interview
Screenshot of Laura Wingate in a Zoom interview
Screenshot of Laura Wingate in a Zoom interview
Screenshot of Laura Wingate in a Zoom interview
Screenshot of Laura Wingate in a Zoom interview
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.